Celltrions Vegzelma becomes Europes top prescribed anticancer drug in two years Celltrions cancer treatment Vegzelma achieves impressive market dominance in Europe within two years ...

Samsung Bioepis also has approval for versions of Roche/Novartis' AMD therapy Lucentis (ranibizumab) and two Roche cancer antibodies, Herceptin (trastuzumab) and Avastin (bevacizumab). The ...

With an additional 15 predicted by 2023, Roche is set fair to weather the 'patent cliff' it is facing with drugs like Avastin (bevacizumab), Herceptin (trastuzumab) and MabThera/Rituxan (rituximab ...

SHANGHAI, China I 5, 2025 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for ...

The approval of trastuzumab in 1998 has significantly improved patients’ outcomes and paved the way for the beginning of advent of targeted approaches in breast cancer treatment. However, primary or ...

Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...

Henlius' commitment to stringent quality standards has been instrumental in achieving EC approval for serplulimab. In 2023, Henlius' manufacturing facilities and production lines of serplulimab ...